Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 73-78

  Borthakur, Gautam ^a   Huang, Xuelin ^a   Kantarjian, Hagop ^a   Faderl, Stefan ^a   Ravandi, Farhad ^a   Ferrajoli, Alessandra ^a   Torma, Ritva ^a   Morris, Gail ^a   Berry, Donald ^a   Issa, Jean Pierre ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myelogenous leukemia; Azacitidine; Cytarabine

Indexed keywords

AZACITIDINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CYTARABINE; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 74949127345     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903318329     Document Type: Article

References (32)

1. Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Update 2004;7:267-278.
2. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-7523.
3. Kroeger H, Jelinek J, Estecio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008;112:1366-1373.
4. Agrawal S, Unterberg M, Koschmieder S, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 2007;67:1370-1377.
5. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007;13:1634-1637.
6. Lee T, Karon M, Momparler RL. Kinetic studies on phosphorylation of 5-azacytidine with the purified uridinecytidine kinase from calf thymus. Cancer Res 1974;34:2482-2488.
7. Grant S, Cadman E. Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts. Cancer Res 1980;40:4000-4006.
8. Plagemann PG, Behrens M, Abraham D. Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Cancer Res 1978;38:2458-2466.
9. Cihak A, Vesely J, Skoda J. Azapyrimidine nucleosides: metabolism and inhibitory mechanisms. Adv Enzyme Regul 1985;24:335-354.
10. Cihak A, Vesely J, Sorm F. Incorporation of 5-azacytidine into liver ribonucleic acids of leukemic mice sensitive and resistant to 5-azacytidine. Biochim Biophys Acta 1965;108:516-518.
11. Weiss JW, Pitot HC. Effects of 5-azacytidine on nucleolar RNA and the preribosomal particles in Novikoff hepatoma cells. Biochemistry 1975;14:316-326.
12. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology 1974;30:405-422.
13. Mohandas T, Sparkes RS, Shapiro LJ. Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation. Science 1981;211:393-396.
14. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
15. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-20-deoxycytidine. J Biol Chem 1982;257:2041-2048.
16. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-3903.
17. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
18. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
19. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998;103:1096-1103.
20. Steuart CD, Burke PJ. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol 1971;233:109-110.
21. Gati WP, Paterson AR, Larratt LM, Turner AR, Belch AR. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 1997;90: 346-353.
22. Colly LP, Peters WG, Richel D, Arentsen-Honders MW, Starrenburg CW, Willemze R. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. Semin Oncol 1987;14(2 Suppl 1):257-261.
23. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-b-D-arabinofuranosylcytosine. Cancer Res 1984;44:5029-5037.
24. Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 2007;13:4225-4232.
25. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-20-deoxycytidine in human cancer cell lines. Blood 2009;113:659-667.
26. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007;63:429-436.
27. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
28. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
29. Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS. Pharmacodynamic and DNA methylation studies of high-dose 1-b-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Cancer Chemother Pharmacol 1989;24:203-210.
30. Neil GL, Berger AE, Bhuyan BK, DeSante DC. Combination chemotherapy of L1210 leukemia with 1-b-D-arabinofuranosylcytosine and 5-azacytidine. Cancer Res 1976;36:1114-1120.
31. Momparler RL, Goodman J, Karon M. In vitro biochemical and cytotoxicity studies with 1-b-D-arabinofuranosylcytosine and 5-azacytidine in combination. Cancer Res 1975;35:2853-2857.
32. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-20-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-1640.